Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2021

View Archived Issues

HepaRegeniX initiates first-in-human trial of HRX-0215

China Pharmaceutical University targets WDR5/MLL1 interaction with DDO-2213

GentiBio closes Series A financing to advance its pipeline of engineered Treg therapies

First patient dosed in phase I study of AVA-6000

IN8bio completes dosing of first cohort in phase I study of INB-100

Janssen describes mutant FimH compositions

Positive interim analysis data from phase II/III study of plonmarlimab in severe COVID-19

Jiangsu Hengrui Medicine and collaborators patent antibacterials

New PTPN11 inhibitors discovered at Betta Pharmaceuticals

Nuvation Bio identifies new adenosine A2a receptor antagonists

SAB-185 potently neutralizes delta and lambda SARS-CoV-2 variants in nonclinical studies

Oxford Vacmedix receives approval for its first-in-human study of OVM-200 cancer vaccine

Lynk initiates dosing in phase I study of its triple-kinase inhibitor LNK-01002

RemeGen completes phase II study of telitacicept in IgAN

FDA clears IND for XeriSol levothyroxine subcutaneous injection

Imatinib preserves Beta-cell function in subjects with type 1 diabetes

Cali Biosciences initiates MERIT-1 study of long-acting ropivacaine for postoperative pain

Further data from phase I study of UV-1 in metastatic melanoma

JadiCell shows superior neurogenesis induction in model of viral-induced cognitive dysfunction

Algernon Pharmaceuticals announces SCLC research program for ifenprodil

Enrollment ongoing in phase II studies of ABBV-154

Marker of neuroaxonal injury is also a marker of worse outcomes in COVID-19 patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...